ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Summary

The goal of this clinical trial is to see if the combination of experimental drug ASTX727 and Nivolumab enhances the antitumor immune response in participants will recurrent or metastatic squamous cell carcinoma of the head and neck. Participants will take a pill called ASTX727 for 4 or 5 days every month followed by an injection of Nivolumab one week after the first dose of study medication.

Timeline

Start

2024-06-01

Primary completion

2025-02-28

Completion

2026-02-28

Drugs

Indications